Celltrion receives acceptance for infliximab biosimilar antibody from Brazils ANVISA Hospira.

Celltrion receives acceptance for infliximab biosimilar antibody from Brazil’s ANVISA Hospira, Inc. The medication will be marketed by Hospira contact . Hospira also markets and markets biosimilar infliximab in 26 European countries and in Canada beneath the brand name Inflectra. This important item has been approved in Brazil for the treatment of: arthritis rheumatoid, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's disease in children and adults, fistulizing Crohn's disease , colitis and ulcerative rectocolitis. Remsima is the first biological medication approved by Brazil's regulator, ANVISA, based on comparability. A comparability study is necessary because under ANVISA's Normative Quality RDC 55/2010, biosimilarity must be proven by direct evaluation with the reference biological drug .

impotance

Related StoriesResearchers reveal why malaria vaccine provides just moderate safety among vaccinated childrenGHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengueHuman malaria parasite molecules share key gene segments with chimp, gorilla malaria parasitesIt is due to the one-celled parasite carried by mosquitoes known as plasmodium, and kills mostly young children. Artemisinin may be the drug of choice for treating multi-drug resistant strains of plasmodium species as found in combination with other drugs it has proved to be nearly 100 percent effective. It is presently extracted from a plant called Artemisia annua commonly known as sweet wormwood, and grown by farmers in Asia.